Call Options

9 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$309.38 - $337.38 $129 Million - $141 Million
-417,400 Reduced 29.15%
1,014,700 $327 Million
Q2 2024

Aug 14, 2024

BUY
$262.75 - $319.31 $74.5 Million - $90.6 Million
283,600 Added 24.69%
1,432,100 $447 Million
Q1 2024

May 15, 2024

BUY
$268.87 - $324.56 $66.2 Million - $79.9 Million
246,200 Added 27.29%
1,148,500 $327 Million
Q4 2023

Feb 14, 2024

SELL
$255.7 - $288.46 $4.63 Million - $5.22 Million
-18,100 Reduced 1.97%
902,300 $260 Million
Q3 2023

Nov 14, 2023

BUY
$218.65 - $271.46 $26.1 Million - $32.4 Million
119,500 Added 14.92%
920,400 $247 Million
Q2 2023

Aug 14, 2023

SELL
$214.27 - $253.37 $12 Million - $14.2 Million
-56,000 Reduced 6.54%
800,900 $178 Million
Q1 2023

May 15, 2023

BUY
$225.79 - $275.2 $26.4 Million - $32.1 Million
116,800 Added 15.78%
856,900 $207 Million
Q4 2022

Feb 14, 2023

SELL
$229.03 - $291.01 $130 Million - $166 Million
-569,700 Reduced 43.5%
740,100 $194 Million
Q3 2022

Nov 14, 2022

SELL
$224.46 - $253.15 $7.86 Million - $8.86 Million
-35,000 Reduced 2.6%
1,309,800 $295 Million

Others Institutions Holding AMGN

About AMGEN INC


  • Ticker AMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 534,931,008
  • Market Cap $141B
  • Description
  • Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...
More about AMGN
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.